Melatonin

Quick links to important sections

Melatonin

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Melatonin

Understanding Melatonin

Melatonin is a hormone naturally produced by the pineal gland, a small endocrine gland located in the center of the brain. It plays a fundamental role in regulating the body's internal biological clock, specifically the sleep-wake cycle, also known as the circadian rhythm.

Natural Production and Function

The synthesis and release of melatonin are chemically influenced by light exposure. During the day, production is suppressed by sunlight or bright artificial light. As darkness falls, the pineal gland increases melatonin secretion, signaling to the body that it is time to prepare for rest. This process helps synchronize the body's physiological functions with the 24-hour day-night cycle.

Melatonin as a Supplement

Beyond the hormone produced biologically within the body, melatonin is also available in synthesized forms. These formulations are typically used to address disruptions in the natural sleep cycle. Unlike many other sleep aids, melatonin is classified as a chronobiotic, meaning it influences the timing of the sleep-wake cycle rather than acting as a traditional sedative.

Role in the Body

While its primary function is the regulation of sleep, melatonin receptors are found throughout various tissues in the body. Research indicates that the hormone interacts with different physiological systems, contributing to the maintenance of the body's internal timing for various biological processes. Its presence is a key factor in how the body distinguishes between physiological 'day' and 'night' states.

Regulatory References

  1. EMA Melatonin (Circadin) Overview
  2. NIH Melatonin Monograph
  3. MedlinePlus, Melatonin: Drug Information

What side effects are possible with Melatonin?

Documented Adverse Reactions and Safety Characteristics

The regulatory framework for Melatonin establishes a profile of documented adverse reactions classified by frequency and the body system affected, consistent with official government prescribing information. These classifications detail the potential effects observed in clinical use and post-marketing surveillance.

Adverse reactions classified as Common (occurring in 1/100 to < 1/10 patients) typically include headache, nasopharyngitis, back pain, and arthralgia. The Uncommon category (1/1,000 to < 1/100 patients) covers reactions across several system organ classes, such as somnolence (drowsiness), dizziness, anxiety, insomnia, nausea, and fatigue. Rare adverse reactions (1/10,000 to < 1/1,000 patients) are also documented, including specific events like syncope or visual acuity reduced.

Specific safety constraints are defined for certain patient groups. The use of the medicine is not recommended in individuals with hepatic impairment (liver disease) or those with autoimmune diseases due to a lack of sufficient clinical data in these populations. Additionally, caution is advised in cases of renal impairment. The documented potential for somnolence means that particular caution is required when engaging in activities that demand complete mental alertness. Use with alcohol is not recommended as it may reduce the medicine's efficacy and increase the risk of central nervous system effects. Officially documented serious adverse reactions are rare and include potential hypersensitivity events such as angioedema.

Overdose and Emergency Response

Melatonin Overdose and when to seek help

Official regulatory documentation describes the overdose profile for Melatonin based on documented clinical manifestations and mandated emergency actions, strictly defining when help must be sought.

Domain Official Regulatory Statement
Documented Presentation The primary clinical sign of over-ingestion is excessive drowsiness or somnolence. More severe CNS manifestations, including fainting and loss of consciousness, are documented in regulatory-aligned patient information.
Severe Outcomes Public health reports highlight severe outcomes in accidental pediatric ingestion cases, including the need for mechanical ventilation and, tragically, death. These outcomes underscore the necessity for strict adherence to mandated emergency protocols.
Mandated Action Upon accidental over-ingestion, the official guidance is to contact your doctor or pharmacist as soon as possible. For severe symptoms, such as loss of consciousness, immediate attention at an Emergency Department is officially required.
Treatment Status Management is restricted to general symptomatic and supportive measures. Regulatory documents consistently state that no specific antidote is known for Melatonin overdose. Control of vital signs may be necessary.
Population Notes Official reports specifically note the significant risk associated with pediatric ingestion. Caution is also documented for individuals with pre-existing hepatic impairment.

The regulatory profile clearly defines the threshold for urgent medical intervention by linking the common manifestation (drowsiness) with the severe potential of life-threatening outcomes, particularly in children. This structure mandates immediate professional medical contact upon the appearance of serious signs.

Therapeutic Uses of Melatonin

Main Uses and Benefits of Melatonin

Melatonin is commonly used to address groups of symptoms that interfere with sleep onset and quality. This application is relevant in clinical settings marked by difficulties falling asleep or maintaining consistent sleep. The medication is generally applied across domains where additional symptomatic support is needed for conditions such as jet lag, delayed sleep-wake phase disorder, and temporary insomnia.

Assisting with Circadian Rhythm and Symptomatic Relief

This domain of use is applicable across conditions characterized by episodic or fluctuating symptom patterns tied to the body's internal clock, often in situations involving shift work or other sleep disruptions. It contributes to easing the overall symptom load and may help support more settled rest, assisting with maintaining functional stability when symptoms become more noticeable. It is considered relevant in general clinical scenarios where symptoms of sleep-related discomfort intensify and supportive relief is needed.

Quick Fact: Support for Sleep-Onset Difficulties

Regulatory References

  1. NIH National Center for Complementary and Integrative Health (NCCIH) overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Melatonin?

Eligibility to use Melatonin is strictly defined by regulatory bodies and often varies based on the specific formulation and medical indication. It is crucial to adhere to these official guidelines.

Populations with Eligibility Restrictions

Classification Population/Condition Official Status (Label-Based)
Contraindicated Known hypersensitivity to Melatonin or any excipient Must not use
Not Recommended Severe hepatic impairment (liver) Use is not advised
Not Recommended Autoimmune diseases Use is not advised
Not Recommended Pregnancy and breastfeeding Use is not advised

Age-Related Eligibility

The primary approved population for specific prescription formulations is adults ge 55 years old for the short-term treatment of primary insomnia. For this specific indication, use is not recommended in children and adolescents under 18 years due to insufficient data. However, some national labels permit use in children ge 2 years old for specific sleep disorders related to neurodevelopmental conditions.

What should I know about interactions with other medicines?

The official regulatory profile for Melatonin is structured by pharmacokinetic and pharmacodynamic interactions documented in government-approved labeling.

Documented Pharmacokinetic Interactions

Melatonin's metabolism is primarily mediated by the CYP1A2 enzyme pathway. Therefore, interactions with substances that modulate this enzyme are explicitly noted in regulatory documents.

  • Increased Exposure: The potent CYP1A2 inhibitor Fluvoxamine formally results in a substantial (up to 17-fold) increase in Melatonin exposure (AUC/Cmax) and co-administration is advised to be avoided. Other agents such as Oestrogens (e.g., in contraceptives or HRT), Cimetidine, and Quinolones are also documented to increase Melatonin plasma concentrations by inhibiting its clearance.
  • Decreased Exposure: Agents that induce CYP1A2, including Cigarette Smoking, Carbamazepine, and Rifampicin, are noted to decrease Melatonin plasma concentrations.

Pharmacodynamic and Substance Restrictions

  • Enhanced Sedation: Melatonin may enhance the sedative properties of CNS depressants, including Benzodiazepines and non-benzodiazepine hypnotics like Zolpidem, and their combination is generally restricted or advised to be avoided.
  • Anticoagulants: Caution is advised when co-administering with Warfarin and other Vitamin K Antagonists due to the potential to increase anticoagulation activity.
  • Alcohol and Food: Alcohol must not be taken concomitantly as it officially reduces the effectiveness on sleep. Furthermore, some official prescribing information advises avoiding carbohydrate-rich meals near administration time.

Population-Specific Notes

Melatonin is not recommended for use in patients with hepatic impairment due to a lack of experience and documented concerns regarding reduced clearance leading to increased exposure. Caution is also advised in patients with renal impairment.

Mechanism of Action

Melatonin's primary action involves acting as an agonist at two principal G-protein coupled receptors in the central nervous system and peripheral tissues: the MT1 and MT2 receptors. These receptors are integral to the regulation of the circadian rhythm.

Activation of the MT1 receptor, primarily located in the suprachiasmatic nucleus (SCN), inhibits the enzyme adenylate cyclase. This molecular interaction reduces the intracellular concentration of the second messenger cyclic AMP (cAMP). The resultant decrease in cAMP triggers a signaling cascade that promotes the opening of potassium channels, leading to neuronal hyperpolarization within the SCN neurons.

The MT2 receptor also contributes to phase shifting by regulating the entrainment of the circadian pacemaker. This combined cellular mechanism signals to the body's systems that the light cycle has ended, facilitating the physiological process of sleep-wake cycle entrainment and resetting the central clock's activity.

Dosage and Administration Information

The administration of prescription-grade Melatonin involves specific instructions concerning dosage, timing, and formulation handling. Melatonin is administered by the oral route in either prolonged-release or immediate-release tablet forms. The usage pattern is once daily, with precise timing dictated by the specific formulation and indication.


Administration Requirements by Formulation

Instruction Category Prolonged-Release Tablet (2 mg for Insomnia 55) Immediate-Release Tablet (3 mg for Jet Lag)
Dosing Schedule 2 mg once daily. Standard 3 mg once daily; maximum 6 mg.
Timing & Food Taken 1 to 2 hours before bedtime and after food. Taken at habitual bedtime; strictly not before 20:00 hr or after 04:00 hr local time. Should be taken separate from meals.
Handling Must be swallowed whole; must not be crushed or chewed. May be crushed or mixed with fluid/soft food in certain pediatric cases.
Duration Limit Short-term use, up to 13 weeks. Maximum of 5 consecutive days per course.

Population and Procedural Constraints

The 2 mg prolonged-release formulation is intended for use in patients aged 55 or over. Dosing is not recommended in patients with moderate or severe hepatic impairment across formulations due to concerns over reduced drug clearance. If a dose is missed for short-term regimens, it should be skipped rather than doubled, and treatment should continue the following day.

Recent Clinical Evidence

Melatonin: Recent Clinical Evidence

Evidence for Key Clinical Situations

Melatonin was evaluated in research contexts exploring three primary areas: primary insomnia, Delayed Sleep-Wake Phase Disorder (DSWPD), and jet lag. For primary insomnia, the research foundation includes Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies primarily examined objective outcomes such as the time it took for participants to fall asleep (Sleep Onset Latency). Findings indicated patterns where these measurements were observed in the Melatonin group compared to control, though meta-analyses reported that the size of the differences measured was small. For DSWPD, research examined changes in schedule timing and internal timing biomarkers like the Dim Light Melatonin Onset (DLMO) in Adults and Children/Adolescents. For jet lag, evidence is based on RCTs that monitored subjective patient ratings of overall jet lag severity and sleep quality following travel across five or more time zones.

Research Gaps and Uncertainty

The scientific literature highlights several areas where certainty remains low and where additional research is needed. A significant limitation across most indications is that the follow-up durations were limited, resulting in insufficient data on long-term outcomes or the durability of any observed changes. Consequently, long-term effects are not fully established. The available evidence in specific populations is also limited, although Older Adults and Children/Adolescents with DSWPD have been evaluated. The findings themselves were mixed or data show patterns related to only small changes in some outcomes, particularly when comparing objective sleep parameters versus patient-reported experience. Furthermore, comparative evidence is lacking in some areas, meaning few studies directly compare Melatonin against established treatments.

Key Studies & References

  1. Melatonin: What You Need to Know (NIH National Center for Complementary and Integrative Health)
  2. MedlinePlus, Melatonin: Drug Information (U.S. National Library of Medicine)

Frequently Asked Questions (FAQ)

Common questions about Melatonin (FAQ)

Q: How quickly does Melatonin usually start working after taking it?

A: Studies on Melatonin's absorption, known as pharmacokinetic properties, indicate that peak levels in the blood are generally reached about 20 to 60 minutes after taking an immediate-release tablet. The onset of the medicine's chronobiotic effect, which helps regulate the sleep cycle, is related to this absorption profile.

Q: Can taking Melatonin affect driving or operating machinery?

A: Yes, official regulatory documents state that Melatonin may cause drowsiness (somnolence). Due to this potential effect, it is advised to use caution before driving or operating machinery until the effects are known. Some product information summaries advise against engaging in these activities for 8 hours after administration.

Q: Is it normal to feel groggy or sleepy the morning after taking Melatonin?

A: Regulatory safety information lists both somnolence (drowsiness) and fatigue as possible adverse reactions. Some patient information summaries specifically cite residual drowsiness or a 'hangover' feeling the morning after use as a reported experience. The documentation of these effects indicates that feeling sleepy the next day is a reported possibility.

Q: Can Melatonin interact with common over-the-counter pain relievers?

A: Regulatory interaction summaries note that nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may interact with Melatonin. These pain relievers could potentially increase or decrease the sedating effects of the medicine. Awareness of this potential interaction is noted in official documentation.

Q: Does Melatonin affect blood sugar levels?

A: Official safety data lists Excretion of glucose in urine as an uncommon documented side effect. Potential interactions with blood sugar-lowering medications are noted in regulatory information.

Q: Does Melatonin interact with herbal or natural supplements?

A: Official sources note that taking herbal remedies which cause drowsiness alongside Melatonin may increase the sedating effects. Beyond this, there is often a lack of sufficient, consistent information to confirm the safety of combining other non-drowsy herbal remedies with the medicine.

Q: Is Melatonin the same as a sleeping pill?

A: Melatonin is classified in official sources as a hormone and a chronobiotic agent, which means its primary role is to regulate and synchronize the body’s sleep-wake cycle. While it does possess sedative qualities and is used for sleep issues, its mechanism of action is distinct from traditional sedative-hypnotic 'sleeping pills'.

Q: Can Melatonin help with sleep problems not related to jet lag?

A: Yes, Melatonin has official indications for issues beyond jet lag. Specific prescription formulations are indicated for the short-term treatment of primary insomnia characterized by poor sleep quality in adults aged 55 years and over. It is also used in specialist settings to help manage longer-term sleep problems related to certain conditions.

Q: Can Melatonin be used for long periods of time?

A: The initial license for some specific formulations is for short-term treatment, typically for up to 13 weeks. While some clinical data exists from studies lasting nearly two years, the need for treatment beyond the initial licensed duration is typically subject to regular evaluation by a healthcare professional.

Q: What are the most common mild side effects reported for Melatonin?

A: The most frequently reported adverse reactions classified as Common (occurring in 1 out of 100 to 1 out of 10 people) in regulatory documents include headache, nasopharyngitis (a common cold), back pain, and arthralgia (joint pain).

Q: Is there any difference between synthetic Melatonin and the body's natural Melatonin?

A: The melatonin used in pharmaceutical products and high-purity supplements is chemically identical to the hormone the body naturally produces. It is synthesized in a laboratory to ensure the product has a consistent, pure, and contaminant-free active ingredient.

Q: Is Melatonin suitable for children or teenagers?

A: Specific prescription formulations are generally not recommended for use in children and adolescents under 18 years due to insufficient safety data and concerns about potential effects on development. However, certain national guidelines permit its use, initiated by a specialist, for specific sleep disorders related to neurodevelopmental conditions in children aged 2 years and over.

Q: Is there a maximum amount of time Melatonin is generally used for?

A: Usage limits depend on the specific condition being addressed. For its licensed use in primary insomnia, treatment is limited to short-term use, typically up to 13 weeks. For jet lag, the duration is typically limited to a maximum of 5 consecutive days. The possibility of longer courses may be discussed with a specialist.

Q: Do older adults react differently to Melatonin compared to younger adults?

A: One specific prescription formulation is licensed primarily for adults aged 55 years and over, indicating the drug's use and safety profile were specifically studied in this older population. Regulatory documents focus on eligibility for use in older patients but do not explicitly detail a generalized difference in reaction compared to younger adults.

Q: Is it possible to become dependent on Melatonin?

A: Available research consensus summarized by health authorities indicates that Melatonin is not habit-forming. It does not typically cause the physical dependency or severe withdrawal symptoms that are associated with certain traditional sedative-hypnotic medications used for sleep.

Q: Can Melatonin cause headaches or dizziness?

A: Yes, regulatory safety documents list headache as a Common adverse reaction, meaning it occurs in between 1 out of 100 and 1 out of 10 patients. Dizziness is listed as an Uncommon adverse reaction, occurring less frequently in documented patient populations.

Q: Does taking Melatonin at the wrong time disrupt the sleep cycle?

A: The timing of administration is highly important because Melatonin's purpose is to synchronize the body's internal clock. Official documents note that taking the medicine at the wrong time (e.g., outside the designated window for jet lag) may result in no effect or even an adverse effect on the resynchronization of the circadian rhythm.

Q: Does the strength of Melatonin relate to how well it works?

A: The correct dose strength is related to the patient's condition and individual need, as well as factors like body weight in certain populations. The labeled strength must be taken as prescribed for the specific licensed indication to help achieve the intended effect on the sleep cycle.

Q: Is there scientific research looking into Melatonin for shift work or unusual schedules?

A: While shift work is not an official indication on all product labels, health authorities acknowledge that this type of work disrupts the circadian rhythm and the natural production of Melatonin. Therefore, Melatonin is commonly studied by researchers as a potential aid for sleep-wake cycle misalignment in people working unusual schedules.

Q: Does weight or body size influence how Melatonin works?

A: Regulatory documents for some specific populations, such as younger patients, indicate that the dose may be determined by body weight (e.g., 0.7 mg/kg up to a maximum dose). This suggests that body size can be a factor in determining the appropriate amount needed for the desired effect.

Q: Why are some Melatonin products labeled 'dietary supplement'?

A: The regulatory status of Melatonin varies significantly across the globe. In some countries, including the United States, certain products are marketed as a dietary supplement rather than a pharmaceutical drug. This means the product is not regulated by the FDA (or equivalent bodies) with the same oversight applied to prescription medications.

Q: Does Melatonin help people fall asleep faster, stay asleep longer, or both?

A: Clinical trials and systematic reviews have observed that Melatonin can contribute to a decrease in the time it takes to fall asleep, a metric known as sleep onset latency. Studies have also indicated that it may be associated with an increase in total sleep time.

Q: What does the term 'non-habit forming' mean when applied to Melatonin?

A: When applied to Melatonin, 'non-habit forming' refers to the consensus from official sources that the medicine has not been reported to cause the psychological or physical dependency or significant withdrawal symptoms that are seen with other sedating medications.

Q: Can Melatonin cause allergic reactions?

A: Melatonin is contraindicated and must not be used by patients who have a known hypersensitivity or allergy to the active ingredient or any of its components. Additionally, rare, but serious, documented adverse reactions include signs of hypersensitivity and angioedema (swelling).

Q: Are there any common misuses of Melatonin that people should be aware of?

A: Regulatory guidelines and associated patient information frequently warn against actions that constitute misuse. These include taking the medicine at the wrong time (e.g., too late in the sleep cycle), taking excessive doses, and for prolonged-release tablets, crushing or chewing the tablet instead of swallowing it whole.

Q: Why is the dosage of Melatonin sometimes very different between products?

A: The difference in dosage is often due to the licensed indication or the regulatory status of the product. Specific strengths are licensed for particular uses (e.g., insomnia in older adults vs. jet lag). Furthermore, doses in widely available unregistered supplement products may vary significantly from the doses used in regulated, prescription-grade medicines.

How should Melatonin be stored and disposed of?

Storage and Disposal of Melatonin

Melatonin must be stored according to official regulatory guidelines to maintain product quality and safety. The product should be stored at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F).

The container must be kept tightly closed and protected from light, moisture, and excessive heat. It is a mandatory requirement to store the medication out of the sight and reach of children.

Disposal

To dispose of unused or expired melatonin, follow any specific instructions on the labeling or consult local waste regulations. Do not flush the product down the toilet or pour it down a drain unless explicitly told to do so by the manufacturer. If no take-back program is available, the product should be mixed with an undesirable substance, sealed in a bag, and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Melatonin found in:

A-Z Index: